1. Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice?
- Author
-
van Royen-Kerkhof A, Vastert BS, Swart JF, and Wulffraat NM
- Subjects
- Adolescent, Anti-Inflammatory Agents economics, Antibodies, Monoclonal economics, Antibodies, Monoclonal, Humanized, Biological Therapy trends, Child, Cost-Benefit Analysis, Etanercept, Europe, Humans, Immunoglobulin G economics, Interleukin 1 Receptor Antagonist Protein economics, Interleukin-1 antagonists & inhibitors, Rheumatic Diseases economics, Rheumatic Diseases immunology, Tumor Necrosis Factor-alpha antagonists & inhibitors, United States, Anti-Inflammatory Agents therapeutic use, Antibodies, Monoclonal therapeutic use, Biological Therapy methods, Immunoglobulin G therapeutic use, Interleukin 1 Receptor Antagonist Protein therapeutic use, Receptors, Tumor Necrosis Factor therapeutic use, Rheumatic Diseases therapy
- Published
- 2014
- Full Text
- View/download PDF